


# PRODUCT INFORMATION



## CB-13

Item No. 10010398

**CAS Registry No.:** 432047-72-8  
**Formal Name:** 1-naphthalenyl[4-(pentyllox)-1-naphthalenyl]-methanone  
**Synonym:** CRA-13  
**MF:** C<sub>26</sub>H<sub>24</sub>O<sub>2</sub>  
**FW:** 368.5  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 220, 333 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

CB-13 is supplied as a crystalline solid. A stock solution may be made by dissolving the CB-13 in an organic solvent purged with an inert gas. CB-13 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of CB-13 in these solvents is approximately 0.2, 5, and 20 mg/ml, respectively.

If aqueous stock solutions are required for biological experiments, they can best be prepared by diluting the organic solvent into aqueous buffers or isotonic saline. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

### Description

CB-13 is a dual agonist of the, central cannabinoid (CB<sub>1</sub>) (IC<sub>50</sub> = 15 nM) and peripheral cannabinoid (CB<sub>2</sub>) (IC<sub>50</sub> = 98 nM) receptors.<sup>1</sup> In rats, oral CB-13 (3 mg/kg) potently blocks CB<sub>1</sub>-dependent neuropathic mechanical hyperalgesia, shows limited brain penetration, and exhibits good oral bioavailability.<sup>1</sup> CB-13 does not possess genotoxic potential, as indicated by negative results in both chromosome aberration and reverse mutation assays.<sup>1</sup> The effects of CB-13 on other aspects of CB signaling have not been assessed.

### Reference

1. Dziadulewicz, E.K., Bevan, S.J., Brain, C.T., *et al.* Naphthalen-1-yl-(4-pentylloxynaphthalen-1-yl)methanone: A potent, orally bioavailable human CB<sub>1</sub>/CB<sub>2</sub> dual agonist with antihyperalgesic properties and restricted central nervous system penetration. *J. Med. Chem.* **50**(16), 3851-3856 (2007).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/26/2024

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM